Clinical Trials

55 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-04-21

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

294 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

55 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06253845 2026-04-01

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

51 enrolled

Phase 1 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07260162 2025-12-03

PERSEVERANCE

24 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

37 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT06351904 2025-09-11

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

72 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05519241 2025-09-02

A Phase I Intravesical PPM Therapy for NMIBC

29 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06181266 2025-08-19

PARADIGM-1

22 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06816017 2025-06-16

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Neoplasms

NCT05085977 2025-01-27

ADVANCED-1

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05085990 2025-01-27

ADVANCED-1

10 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06186414 2025-01-15

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

152 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Non-Muscle Invasive Bladder Neoplasms

NCT06448364 2024-11-06

LTbR

Phase 1 Terminated

4 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT06632964 2024-10-09

A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

16 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03191578 2023-07-14

RUTIVAC-1

44 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05259397 2023-03-08

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03854721 2023-03-03

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

6 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02316171 2022-07-27

CANON

16 enrolled 8 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04819399 2022-04-05

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

30 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03421236 2021-04-28

Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

25 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04109092 2020-12-14

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04089163 2020-03-30

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03053635 2018-08-20

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

6 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02852564 2017-08-22

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Heartburn, Neoplasms

NCT01498172 2015-02-04

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

23 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01458847 2012-11-12

Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Recurrence

NCT00959868 2012-02-13

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

36 enrolled

Neuronopathy, Distal Hereditary Motor, Type IIB, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00782587 2010-02-08

IPOP

14 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT00109655 2008-10-03

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

75 enrolled